Anorexigenic effects of GLP-1 and its analogues

Handbook of Experimental Pharmacology

Volumn 209, Issue , 2012, Pages 185-207

  Gallwitz, Baptist ^a  

^a Medizinische Klinik IV   (Germany)

Author keywords

Bariatric surgery; GLP 1; GLP 1 receptor agonists; Gut brain axis; Incretins; Obesity

Indexed keywords

ALBIGLUTIDE; ANTIOBESITY AGENT; DULAGLUTIDE; EXENDIN 4; EXENDIN [9-39]; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; LIRAGLUTIDE; LIXISENATIDE; PEPTIDE YY; UNCLASSIFIED DRUG; ANOREXIGENIC AGENT; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR;

ANOREXIA; ARTICLE; BARIATRIC SURGERY; BLOOD BRAIN BARRIER; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG RECEPTOR BINDING; ENERGY BALANCE; FOOD INTAKE; GASTROINTESTINAL MOTILITY; GLUCOSE HOMEOSTASIS; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; INSULIN RESISTANCE; MOLECULAR INTERACTION; NEUROMODULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHARMACOLOGICAL BLOCKING; PLEIOTROPY; PRIORITY JOURNAL; SATIETY; STOMACH EMPTYING; ANIMAL; BODY WEIGHT; BRAIN; DRUG EFFECT; DRUG POTENTIATION; EATING; METABOLISM; PSYCHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APPETITE DEPRESSANTS; APPETITE REGULATION; BARIATRIC SURGERY; BODY WEIGHT; BRAIN; EATING; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; OBESITY; RECEPTORS, GLUCAGON; SATIETY RESPONSE; SIGNAL TRANSDUCTION;

EID: 84856354755     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-24716-3_8     Document Type: Article

References (118)

1. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, Ghatei MA, Bloom SR2005) The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagonlike peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044:127-131 (Pubitemid 40616060)
2. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D2009) Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 94:1843-1852
3. Ahren B2004) GLP-1 and extra-islet effects. Horm Metab Res 36:842-845 (Pubitemid 40115908)
4. Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME, NN8022-1807 Study Group2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374:1606-1616
5. Baggio LL, Drucker DJ2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157 (Pubitemid 46711096)
6. Baggio LL, Huang Q, Brown TJ, Drucker DJ2004) A recombinant human glucagon-like peptideGLP)-1-albumin proteinalbugon) mimics peptidergic activation of GLP-1R-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53:2492-2500 (Pubitemid 39145610)
7. Baggio LL, Huang Q, Cao X, Drucker DJ2008) An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 134:1137-1147 (Pubitemid 351451971)
8. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR2002) Guthormone PYY(3-36) physiologically inhibits food intake. Nature 418:650-654
9. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR2003) Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349:941-948 (Pubitemid 37064767)
10. Beak SA, Small CJ, Ilovaiskaia I, Hurley JD, Ghatei MA, Bloom SR, Smith DM1996) Glucagonlike peptide-1GLP-1) releases thyrotropinTSH): characterization of binding sites for GLP-1 on a-TSH cells. Endocrinology 137:4130-4138 (Pubitemid 26321857)
11. Beak SA, Heath MM, Small CJ, Morgan DG, Ghatei MA, Taylor AD, Buckingham JC, Bloom SR, Smith DM1998) Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line. J Clin Invest 101:1334-1341 (Pubitemid 28145250)
12. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC1983) Exon duplication and divergence in the human preproglucagon gene. Nature 304:368-371 (Pubitemid 13072761)
13. Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE2010) Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetesDURATION-2): a randomised trial. Lancet 376:431-439
14. Boggiano MM, Chandler PC, Oswald KD, Rodgers RJ, Blundell JE, Ishii Y, Beattie AH, Holch P, Allison DB, Schindler M, Arndt K, Rudolf K, Mark M, Schoelch C, Joost HG, Klaus S, Thone- Reineke C, Benoit SC, Seeley RJ, Beck-Sickinger AG, Koglin N, Raun K, Madsen K, Wulff BS, Stidsen CE, Birringer M, Kreuzer OJ, Deng XY, Whitcomb DC, Halem H, Taylor J, Dong J, Datta R, Culler M, Ortmann S, Castaneda TR, Tschop M2005) PYY3-36 as an anti-obesity drug target. Obesity Rev 6:307-322 (Pubitemid 41578600)
15. Brubaker PL, Drucker DJ2004) Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145:2653-2659 (Pubitemid 38686211)
16. Bungo T, Ando R, Kawakami S-I, Ohgushi A, Furuse M2001a) The role of central catecholaminergic systems in regulation of food intake of chicks. J Poult Sci 38:35-40 (Pubitemid 33319491)
17. Bungo T, Kawakami S-I, Ohgushi A, Sashihara K, Saito N, Sugahara K, Hasegawa S, Denbow DM, Furuse M(2001b) Intracerebroventricular injection of fusaric acid attenuates the anorexia by glucagon-like peptide-1 in the neonatal chick. Pharmacol Biochem Behav 70:251-255 (Pubitemid 33049935)
18. Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, Wilhelm K, Trautmann M, Shen LZ, Porter LE2010) DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 33:1255-1261
19. Christensen M, Knop FK, Vilsbøll T, Holst JJ2011) Lixisenatide for type 2 diabetes mellitus. Expert Opin Investig Drugs 20:549-557
20. Chuang VT, Kragh-Hansen U, Otagiri M2002) Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 19:569-577 (Pubitemid 34553662)
21. Courreges JP, Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Verhoeven R, Buganova I, Madsbad S2008) Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med 25:1129-1131
22. Creutzfeldt W1979) The incretin concept today. Diabetologia 16:75-85 (Pubitemid 9231263)
23. Cummings D, Overduin J, Foster-Schubert K, Carlson M2007) Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery. Surg Obes Relat Dis 3:109-115 (Pubitemid 46444709)
24. Cummings D, Foster-Schubert K, Carlson M, Shannon M, Overduin J2008) Possible hormonal mechanisms mediating the effects of bariatric surgery. In: Pitomobo C, Jones K, Higa K, Pareja Jeds) Obesity surgery: principles and practice. McGraw-Hill, New York, NY, pp 137-147
25. D'Alessio D2008) Intestinal hormones and regulation of satiety: the case for CCK, GLP-1, PYY, and Apo A-IV. JPEN J Parenter Enteral Nutr 32:567-568
26. D'Alessio DA, Vogel R, Prigeon R, Laschansky E, Koerker D, Eng J, Ensinck JW1996) Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 97:133-138 (Pubitemid 26021703)
27. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, Ghatei MA, Bloom SR2004) Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145:2687-2695 (Pubitemid 38686215)
28. Delgado-Aros S, Kim DY, Burton DD, Thomforde GM, Stephens D, Brinkmann BH, Vella A, Camilleri M2002) Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol 282: G424-G431 (Pubitemid 34651657)
29. Diamant M, Van GL, Stranks S, Northrup J, Cao D, Taylor K, Trautmann M2010) Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetesDURATION-3): an open-label randomised trial. Lancet 375:2234-2243
30. Dirksen C, Hansen DL, Madsbad S, Hvolris LE, Naver LS, Holst JJ, Worm D2010) Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastricfeeding and is associated with xaggerated GLP-1 secretion: a case report. Diabetes Care 33:375-377
31. Drucker DJ2006) The biology of incretin hormones. Cell Metab 3:153-165
32. Drucker DJ, Nauck MA2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705 (Pubitemid 46048557)
33. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372:1240-1250
34. Egan JM, Margolskee RF2008) Taste cells of the gut and gastrointestinal chemosensation. Mol Interv 8:78-81 (Pubitemid 351549906)
35. Elahi D, Nagulesparan M, Hershcopf RJ, Muller DC, Tobin JD, Blix PM, Rubenstein AH, Unger RH, Andres R1982) Feedback inhibition of insulin secretion by insulin: relation to the hyperinsulinemia of obesity. N Engl J Med 306:1196-1202 (Pubitemid 12158849)
36. Fehmann HC, Habener JF1992) Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 130:159-166
37. Flint A, Raben A, Astrup A, Holst JJ1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:515-520 (Pubitemid 28084232)
38. Flint A, Raben A, Ersbøll AK, Holst JJ, Astrup A2001) The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25:781-792 (Pubitemid 32601369)
39. Furuse M, Matsumoto M, Saito N, Sugahara K, Hasegawa S1997) The central corticotropinreleasing factor and glucagon-like peptide-1 in food intake of the neonatal chick. Eur J Pharmacol 339:211-213
40. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B2009) Liraglutide versus glimepiride monotherapy for type 2 diabetesLEAD-3 Mono): a randomised,52-week, phase III, double-blind, parallel-treatment trial. Lancet 373:473-481
41. Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B, LEAD-3Mono) Study Group2011) Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 13:348-356
42. Glaesner W, Vick AM, Millican R, Ellis B, Tschang SH, Tian Y, Bokvist K, Brenner M, Koester A, Porksen N, Etgen G, Bumol T2010) Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 26:287-296
43. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B1993) Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268:19650-19655 (Pubitemid 23270754)
44. Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP1995) Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 7:2294-2300
45. Gromada J, Rorsman P, Dissing S, Wulff BS1996) Stimulation of cloned human glucagon-like peptide 1 receptor expressed in HEK 293 cells induces cAMP-dependent activation of calciuminduced calcium release. FEBS Lett 373:182-186
46. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, Beglinger C1999) Glucagonlike peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276:R1541-R1544 (Pubitemid 29249681)
47. Holst JJ2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409-1439 (Pubitemid 350041474)
48. Holst JJ, Deacon CF, Vilsbøll T, Krarup T, Madsbad S2008) Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med 14:161-168
49. Imeryuz N, Yeden BC, Bozkurt A, Copkun T, Villanueva-Peñacarrillo ML, Ulusoy NB1997) Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 273:G920-G927
50. Jang HJ, Kokrashvili Z, Theodorakis MJ, Carlson OD, Kim BJ, Zhou J, KimHH XuX, Chan SL, Juhaszova M, Bernier M, Mosinger B, Margolskee RF, Egan JM2007) Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci USA 104:15069-15074 (Pubitemid 47619594)
51. Jin SL, Han VK, Simmons JG, Towle AC, Lauder JM, Lund PK1988) Distribution of glucagonlike peptide IGLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 271:519-532
52. Kakei M, Yada T, Nakagawa A, Nakabayashi H2002) Glucagon-like peptide-1 evokes action potentials and increases cytosolic Ca2+ in rat nodose ganglion neurons. Auton Neurosci 102:39-44 (Pubitemid 35305005)
53. Kashyap SR, Daud S, Kelly KR, Gastaldelli A, Win H, Brethauer S, Kirwan JP, Schauer PR2010) Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J ObesLond) 34:462-471
54. Kim D, Macconell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K2007) Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30:1487-1493 (Pubitemid 46871159)
55. Kinzig KP, D'Alessio DA, Seeley RJ2002) The diverse roles of specific GLP-1Rs in the control of food intake and the response to visceral illness. J Neurosci 22:10470-10476 (Pubitemid 35416883)
56. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24:275-286 (Pubitemid 351160260)
57. Larsen PJ, Tang-Christensen M, Holst JJ, ørskov C1997a) Distribution of glucagon-like peptide- 1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77:257-270 (Pubitemid 27060323)
58. Larsen PJ, Tang-Christensen M, Jessop DS1997b) Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 138:4445-4455 (Pubitemid 27408493)
59. Ling Z, Wu D, Zambre Y, Flamez D, Drucker DJ, Pipeleers DG, Schuit FC2001) Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch 438:382-387 (Pubitemid 32285364)
60. Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, Wilding I, Nauck M, Horowitz M2008) Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 151:123-129
61. Ma X, Bruning J, Ashcroft FM2007) Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons. J Neurosci 27:7125-7129 (Pubitemid 47037544)
62. Madsbad S2009) Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonistsincretin mimetics) - preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 23:463-477
63. Madsbad S, Kielgast U, Asmar M, Deacon C, Torekov SS, Holst JJ2011) An overview of onceweekly GLP-1 receptor agonists - available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 13:394-407
64. Meeran K, O'Shea D, Edwards CM, Turton MD, Heath MM, Gunn I, Abusnana S, Rossi M, Small CJ, Goldstone AP, Taylor GM, Sunter D, SteereJ CSJ, Ghatei MA, Bloom SR1999) Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-9-39) alters body weight in the rat. Endocrinology 140:244-250 (Pubitemid 29011165)
65. Meier JJ, Gallwitz B, Schmidt WE, Nauck MA2002) Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 440:269-279 (Pubitemid 34460704)
66. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA2003a) Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88:2719-2725 (Pubitemid 36733545)
67. Meier S, Hucking K, Ritzel R, Holst JJ, Schmiegel WH, Nauck MA2003b) Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1GLP-1) in healthy volunteers. Horm Metab Res 35:551-556 (Pubitemid 37260421)
68. Meier JJ, Kemmeries G, Holst JJ, Nauck MA2005) Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 54:2212-2218 (Pubitemid 40911286)
69. Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, Elahi D2003) Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care 26:2835-2841 (Pubitemid 37205555)
70. Nagai K, Tsuchiya K, Ezaki T, Tsuchiya M, Ohgawara H2004) Effect of GLP-1glucagon-like peptide 1:7-36 amide) on porcine pancreatic endocrine cell proliferation and insulin secretion. Pancreas 28:138-145 (Pubitemid 38269773)
71. Nakade Y, Tsukamoto K, Pappas TN, Takahashi T2006) Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats. Brain Res 1111:117-121 (Pubitemid 44331186)
72. Naslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rossner S, Hellstrom PM1999) Energy intake and appetite are suppressed by glucagon-like peptide-1GLP-1) in obese men. Int J Obes Relat Metab Disord 23:304-311 (Pubitemid 29118862)
73. Naslund E, King N, Mansten S, Adner N, Holst JJ, Gutniak M, Hellstrom PM2004) Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr 91:439-446 (Pubitemid 38386908)
74. Nauck M, Stockmann F, Ebert R, Creutzfeldt W1986) Reduced incretin effect in type 2noninsulin- dependent) diabetes. Diabetologia 29:46-52 (Pubitemid 16162741)
75. Nauck MA, Kleine N, ørskov C, Holst JJ, Willms B, Creutzfeldt W1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 17-36 amide) in type 2noninsulin- dependent) diabetic patients. Diabetologia 36:741-744 (Pubitemid 23218642)
76. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, ørskov C, Ritzel R, Schmiegel WH1997) Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273:E981-E988
77. ørskov C, Holst JJ, Poulsen SS, Kirkegaard P1987) Pancreatic and intestinal processing of proglucagon in man. Diabetologia 30:874-881 (Pubitemid 18003670)
78. ørskov C, Poulsen SS, Moller M, Holst JJ1996) Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 45:832-835 (Pubitemid 26168585)
79. Patrita A, Aisa M, Annetti C, Sidoni A, Galli F, Ferri I, Gullà N, Donini A2007) How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and b-cell function in Goto-kakizaki rats through enhanced proglucagon gene expression and L-cell number. Surgery 142:74-85 (Pubitemid 47042093)
80. Pellissier S, Sasaki K, Le-Nguyen D, Bataille D, Jarrousse C2004) Oxyntomodulin and glicentin are potent inhibitors of the fed motility pattern in small intestine. Neurogastroenterol Motil 16:455-463 (Pubitemid 39140641)
81. Peterli R, Wolnerhanssen B, Peters T, Devaux N, Kern B, Christoffel-Courtin C, Drewe J, von Flue M, Beglinger C2009) Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg 250:234-241
82. Pitomobo C2008) Central nervous system regulation and hormonal signaling. In: Pitomobo C, Jones K, Higa K, Pareja Ceds) Obesity surgery: principles and practice. McGraw-Hill, New York, NY
83. Raufman JP, Singh L, Singh G, Eng J1992) Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. J Biol Chem 267:21432-21437
84. Reimer RA2006) Meat hydrolysate and essential amino acid-induced glucagon-like peptide-1 secretion, in the human NCI-H716 enteroendocrine cell line, is regulated by extracellularsignal-regulated kinase1/2 and p38 mitogen-activated protein kinases. J Endocrinol 191:159-170 (Pubitemid 44756518)
85. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M2009) Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 32:1880-1886
86. Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J, Diamond E2004) The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240:236-242 (Pubitemid 38963013)
87. Salehi M, Vahl TP, D'Alessio DA2008) Regulation of islet hormone release and gastric emptying by endogenous GLP-1 following glucose ingestion. J Clin Endocrinol Metab 93:4909-4916
88. Schirra J, Katschinski M, Weidmann C, Schafer T, Wank U, Arnold R, Goke B1996) Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 97:92-103 (Pubitemid 26021698)
89. Schirra J, Kuwert P, Wank U, Leicht P, Arnold R, Goke B, Katschinski M1997) Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. Proc Assoc Am Physicians 109:84-97 (Pubitemid 27161053)
90. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, Goke B2006) Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 55:243-251 (Pubitemid 43117285)
91. Schmidtler J, Dehne K, Allescher HD, Schusdziarra V, Classen M, Holst JJ, Polack A, Schepp W1994) Rat parietal cell receptors for GLP-1-(7-36) amide: Northern blot, cross-linking, and radioligand binding. Am J Physiol 267:G423-G432
92. Schnabel CA, Wintle M, Kolterman O2006) Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes. Vasc Health Risk Manag 2:69-77
93. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG2000) Central nervous system control of food intake. Nature 404:661-671 (Pubitemid 30205071)
94. Seeley RJ, Blake K, Rushing PA, Benoit S, Eng J, Woods SC, D'Alessio D2000) The role of CNS glucagon-like peptide-17-36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci 20:1616-1621 (Pubitemid 30220440)
95. Seo S, Ju S, Chung H, Lee D, Park S2008) Acute effects of glucagon-like peptide-1 on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats. Endocr J 55:867-874
96. Shin YK, Martin B, Golden E, Dotson CD, Maudsley S, Kim W, Jang HJ, Mattson MP, Drucker DJ, Egan JM, Munger SD2008) Modulation of taste sensitivity by GLP-1 signaling. J Neurochem 106:455-463 (Pubitemid 351840219)
97. Shughrue PJ, Lane MV, Merchenthaler I1996) Glucagon-like peptide-1 receptorGLP1-R) mRNA in the rat hypothalamus. Endocrinology 137:5159-5162 (Pubitemid 26403362)
98. Silvestre RA, Rodríguez-Gallardo J, Egido EM, Marco J2003) Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas. Eur J Pharmacol 469:195-200 (Pubitemid 36629566)
99. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP2006) Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12:694-699 (Pubitemid 44881367)
100. St Onge EL, Miller SA2011) Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes. Expert Opin Biol Ther 10:801-806
101. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RG, Greig NH, Egan JM2000) Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141:1936-1941 (Pubitemid 32274340)
102. Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Møller M, Sheikh SP1996) Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 271:R848-R856
103. Tang-Christensen M, Vrang N, Larsen PJ1998) Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 47:530-537 (Pubitemid 28160441)
104. Thibaudeau K, Robitaille M, Wen S et al2006) CJC-1134-PC: an exendin-4 conjugate with extended pharmacodynamic profiles in rodents. Diabetes 55(suppl 1):A103
105. Thomas S, Schauer P2010) Bariatric surgery and the gut hormone response. Nutr Clin Pract 25:175-182
106. Tschop M, Castaneda T, Joost HG, Thone-Reineke C, Ortmann S, Klaus S, Hagan HH, Chandler PC, Oswald KD, Benoit SC, Seeley RJ, Kinzig KP, Moran TH, Beck-Sickinger AG, Koglin N, Rodgers RJ, Blundell JE, Ishii Y, Beattie AH, Holch P, Allison DB, Raun K, Madsen K, Wulff BS, Stidsen CE, Birringer M, Kreuzer O, Schindler M, Arndt K, Rudolf K, Mark M, Deng XY, Withcomb DC, Halem H, Taylor J, Dong J, Datta R, Culler M, Craney S, Flora D, Smiley D, Heiman ML2004) Does gut hormone PYY3-36 decrease food intake in rodents? Nature 430:165-166
107. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69-72 (Pubitemid 26008136)
108. Van Dijk G, Thiele TE, Donahey JC, Campfield LA, Smith FJ, Burn P, Bernstein IL, Woods SC, Seeley RJ1996) Central infusions of leptin and GLP-1-(7-36) amide differentially stimulate c-FLI in the rat brain. Am J Physiol 271:R1096-R1100
109. Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Dunning BE, Foley JE, Rizza RA, Camilleri M2007) Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 56:1475-1480 (Pubitemid 46715627)
110. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, Long SJ, Morgan LM, Holst JJ, Astrup A2001) A meta-analysis of the effect of glucagon-like peptide-17-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86:4382-4389 (Pubitemid 32848563)
111. Vetter ML, Cardillo S, Rickels MR, Iqbal N2009) Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med 150:94-10
112. Vrang N, Phifer CB, Corkern MM, Berthoud HR2003) Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons. Am J Physiol Regul Integr Comp Physiol 285: R470-R478 (Pubitemid 36898916)
113. Wang GJ, Tomasi D, Backus W, Wang R, Telang F, Geliebter A, Korner J, Bauman A, Fowler JS, Thanos PK, Volkow ND2008) Gastric distention activates satiety circuitry in the human brain. Neuroimage 39:1824-1831
114. Wang M, Matheson S, Picard J, Pezzullo J, Ulich T2009) PC-DACTM): exendin-4CJC-1134- PC) significantly reduces HbA1c and body weight as an adjunct therapy to metformin: two randomized, double-blind, placebo-controlled, 12 week, phase II studies in patients with type 2 diabetes mellitus. Diabetes 58(suppl 1):A148
115. Wellendorph P, Johansen LD, Brauner-Osborne H2009) Molecular pharmacology of promiscuous seven transmembrane receptors sensing organic nutrients. Mol Pharmacol 76:453-465
116. Wettergren A, Wøjdemann M, Meisner S, Stadil F, Holst JJ1997) The inhibitory effect of glucagon-like peptide-1GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 40:597-601 (Pubitemid 27278325)
117. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M1999) Glucoselowering and insulin-sensitizing actions of exendin-4: studies in obese diabeticob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeysMacacamulatta). Diabetes 48:1026-1034 (Pubitemid 29226349)
118. Zander M, Madsbad S, Madsen JL, Holst JJ2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and b-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830 (Pubitemid 34233752)